(Q44351529)

2 December 2017

title

Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase (English)

1 reference

2 December 2017

8

1 reference

2 December 2017

Christiane Stahl-Hennig

12

object named as

Christiane Stahl-Hennig

1 reference

2 December 2017

9

Heribert Stoiber

1 reference

2 December 2017

6

Monika Franz

1 reference

2 December 2017

You S Suh

1

1 reference

2 December 2017

Ki S Park

2

1 reference

2 December 2017

Ulrike Sauermann

3

1 reference

2 December 2017

Kwang S Kim

4

1 reference

2 December 2017

So S Ahn

5

1 reference

2 December 2017

Reiner Schulte

7

1 reference

2 December 2017

Kilaus Uberla

10

1 reference

2 December 2017

Gerhard Hunsmann

11

1 reference

2 December 2017

Young C Sung

13

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 December 2008

1 reference

2 December 2017

number of pages

9

1 reference

inferred from page(s)

published in

Vaccine

1 reference

2 December 2017

volume

26

1 reference

2 December 2017

issue

51

1 reference

2 December 2017

page(s)

6690-6698

1 reference

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Clinical and epidemiologic features of primary HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Mhc-DQ-DRB haplotype analysis in the rhesus macaque: evidence for a number of different haplotypes displaying a low allelic polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Mhc class I haplotypes associated with survival time in simian immunodeficiency virus (SIV)-infected rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T lymphocyte responses for DNA immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met as a novel adjuvant for DNA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Titration and characterization of two rhesus-derived SIVmac challenge stocks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

A formalin-inactivated whole SIV vaccine confers protection in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

The major histocompatibility complex class II alleles Mamu-DRB1*1003 and -DRB1*0306 are enriched in a cohort of simian immunodeficiency virus-infected rhesus macaque elite controllers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Control of simian immunodeficiency virus SIVmac239 is not predicted by inheritance of Mamu-B*17-containing haplotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Personality and serotonin transporter genotype interact with social context to affect immunity and viral set-point in simian immunodeficiency virus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Role of HCV coinfection towards disease progression and survival in HIV-1 infected children: a follow-up study of 10 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

The replicative capacity of rhesus macaque peripheral blood mononuclear cells for simian immunodeficiency virus in vitro is predictive of the rate of progression to AIDS in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

HIV CTL escape: at what cost?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Increased Natural Killer Cell Activity in Viremic HIV-1 Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

AIDS research. Promising AIDS vaccine's failure leaves field reeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

Simian immunodeficiency virus DNA vaccine trial in macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

7 January 2021

inferred from DOI database lookup

Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

7 January 2021

inferred from DOI database lookup

Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.055

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/J.VACCINE.2008.07.055

1 reference

2 December 2017

1 reference